Structural and immunological differences in Plasmodium falciparum sexual stage transmission-blocking vaccines comprised of Pfs25-EPA nanoparticles
Abstract Development of a malaria vaccine that blocks transmission of different parasite stages to humans and mosquitoes is considered critical for elimination efforts. A vaccine using Pfs25, a protein on the surface of zygotes and ookinetes, is under investigation as a transmission-blocking vaccine...
Main Authors: | Nicholas J. MacDonald, Kavita Singh, Karine Reiter, Vu Nguyen, Richard Shimp, Apostolos G. Gittis, Beth Chen, Martin Burkhardt, Baoshan Zhang, Zhixiong Wang, Raul Herrera, Mackenzie Moler, Duck-Yeon Lee, Sachy Orr-Gonzalez, Jessica Herrod, Lynn E. Lambert, Kelly M. Rausch, Olga Muratova, David S. Jones, Yimin Wu, Albert J. Jin, David N. Garboczi, Patrick E. Duffy, David L. Narum |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-04-01
|
Series: | npj Vaccines |
Online Access: | https://doi.org/10.1038/s41541-023-00655-5 |
Similar Items
-
Preclinical evaluations of Pfs25-EPA and Pfs230D1-EPA in AS01 for a vaccine to reduce malaria transmission
by: Kelly M. Rausch, et al.
Published: (2023-07-01) -
Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults.
by: Kawsar R Talaat, et al.
Published: (2016-01-01) -
mRNA vaccines expressing malaria transmission-blocking antigens Pfs25 and Pfs230D1 induce a functional immune response
by: Puthupparampil V. Scaria, et al.
Published: (2024-01-01) -
Design of a stabilized non-glycosylated Pfs48/45 antigen enables a potent malaria transmission-blocking nanoparticle vaccine
by: Thayne H. Dickey, et al.
Published: (2023-02-01) -
Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.
by: Yimin Wu, et al.
Published: (2008-07-01)